Grey Wolf reels in $49M to enter the clinic for new immunotherapy target
When he finds the time to go fly fishing, Peter Joyce says gray wulffs, or mayfly mimics, are his good luck charm — he always catches a fish when he uses them. Joyce has now brought in $49 million in a Series B round for his biotech company Grey Wolf Therapeutics.
The Oxford, UK cancer biotech plans to use the funds to bring its first asset into human trials in the coming month or two, according to Joyce. Pfizer Ventures and Earlybird Venture Capital co-led the round, which the startup disclosed Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.